ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 1475

Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly

Roxana Coras1,2, Rekha Narasimhan1, Arthur Kavanaugh3, Lourdes Mateo4, Oswald Quehenberger5, Melania Martinez-Morillo6 and Monica Guma1,2, 1Medicine, University of California San Diego, La Jolla, CA, 2Medicine, Autonomous University of Barcelona, Bellatera, Spain, 3University of California, San Diego, School of Medicine, La Jolla, CA, 4Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5Pharmacology, Medicine, University of California San Diego, La Jolla, CA, 6Rheumatology, Germans Trias i Pujol University Hospital, Barcelona, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Arthritis, Elderly, Inflammation, lipids and outcomes

Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Elderly-onset RA, EORA, which is defined as rheumatoid arthritis (RA) starting at >60 years of age, has received less attention than young-onset RA. Polymyalgia rheumatica (PMR) is also a common rheumatic disease in the elderly. Eicosanoids are biological lipids that serve a specific role as either activators or suppressors of systemic inflammation and have been involved in the development and progression of arthritis. We hypothesized that eicosanoid-related perturbations are related to arthritic symptoms in the elderly, and by defining the eicosanoid profile we might be able to define elements of inflammation pathobiology in this population.

Methods: ARTIEL (Arthritis in the Elderly) is a recent collection cohort with newly diagnosed arthritis in patients older than 60 years, with blood samples collected at baseline (pre-treatment), 1, 3 and 12 months after treatment, along with physician and patient outcome measures through 12 months. They are compared with randomly control individuals of the same age and gender. A thorough clinical examination was conducted. Patients completed a health assessment questionnaire (HAQ). Disease activity score (DAS)28CRP was calculated. Serum eicosanoids were determined by mass spectrometry at baseline and after 3 months of treatment and were classified in groups according to their eicosanoid precursor: eicosapentaenoic acid (EPA), docosohexanoic acid (DHA) or arachidonic acid (AA). Data processing and statistical analysis were performed in R.

Results: 64 patients (average: 75.15, standard deviation (SD) 6.80) and 18 controls (average: 75.39, SD, 6.04) were analyzed. Of these, 44 were diagnosed with RA and 20 with PMR. At the start of the study, patients had a mean DAS28CRP of 5.72 (SD, 1.05), mean HAQ was 1.64 (SD, 0.73). In addition, 84% of the patients reported scapular pain, and 56% of the patients reported pelvic pain at baseline. After three months of treatment, patients had a DAS28CRP of 2.38 (SD, 1.23), and a HAQ of 0.36 (SD, 0.41). As shown in table 1, several eicosanoids, especially anti-inflammatory species derived from EPA and DHA were significantly downregulated in patients at the start of the study as compared to normal controls. Moreover, similar anti-inflammatory species were even further downregulated in patients with DAS >5.1 compared to patients with DAS<5.1. Three months after treatment, the levels of anti-inflammatory species derived from EPA and DHA went back to normal in responders (DAS28CRP<3.2). However, new proinflammatory species from AA were significantly elevated in non-responder patients (table 1).

Conclusion: These results suggest that certain eicosanoids may be key effectors in arthritis in the elderly and that the disbalance between pro and anti-inflammatory eicosanoids before and after treatment might be related to clinical and therapeutic outcomes in this population.


Disclosure: R. Coras, None; R. Narasimhan, None; A. Kavanaugh, None; L. Mateo, None; O. Quehenberger, None; M. Martinez-Morillo, None; M. Guma, None.

To cite this abstract in AMA style:

Coras R, Narasimhan R, Kavanaugh A, Mateo L, Quehenberger O, Martinez-Morillo M, Guma M. Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/eicosanoid-mediators-of-systemic-inflammation-and-arthritis-in-the-elderly/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eicosanoid-mediators-of-systemic-inflammation-and-arthritis-in-the-elderly/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology